You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Express Scripts
Boehringer Ingelheim
Baxter
Merck
Colorcon
McKesson

Last Updated: February 18, 2020

DrugPatentWatch Database Preview

Ozenoxacin - Generic Drug Details

See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for ozenoxacin and what is the scope of freedom to operate?

Ozenoxacin is the generic ingredient in one branded drug marketed by Ferrer Internacional and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Ozenoxacin has fifty patent family members in twenty-five countries.

There is one drug master file entry for ozenoxacin. Two suppliers are listed for this compound.

Summary for ozenoxacin
International Patents:50
US Patents:3
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 1
Suppliers / Packagers: 2
Bulk Api Vendors: 23
Clinical Trials: 2
Patent Applications: 17
DailyMed Link:ozenoxacin at DailyMed
Recent Clinical Trials for ozenoxacin

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ferrer Internacional S.A.Phase 3

See all ozenoxacin clinical trials

Pharmacology for ozenoxacin
Synonyms for ozenoxacin
1-cyclopropyl-8-methyl-7-(5-methyl-6-(methylamino)pyridin-3-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
245765-41-7
AKOS032947315
BCP16621
CHEBI:136050
CHEMBL3990047
CS-0003657
D09544
DB12924
EX-A2693
FT-0701296
HY-14957
KB-80783
Ozenoxacin (JAN/INN)
Ozenoxacin [INN:JAN]
Ozenoxacin Cream
Ozenoxacin; T-3912
SB16801
SCHEMBL1711829
T 3912
T-3912
UNII-V0LH498RFO
V0LH498RFO
Xepi
ZINC1483896

US Patents and Regulatory Information for ozenoxacin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferrer Internacional XEPI ozenoxacin CREAM;TOPICAL 208945-001 Dec 11, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ferrer Internacional XEPI ozenoxacin CREAM;TOPICAL 208945-001 Dec 11, 2017 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ferrer Internacional XEPI ozenoxacin CREAM;TOPICAL 208945-001 Dec 11, 2017 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for ozenoxacin

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2344130 300884 Netherlands   Start Trial PRODUCT NAME: OZENOXACIN; REGISTRATION NO/DATE: ES/H/414/1/DC 20170519
2344130 C201730036 Spain   Start Trial PRODUCT NAME: OZENOXACINO; NATIONAL AUTHORISATION NUMBER: 82357-ES/H/0414/001/DC; DATE OF AUTHORISATION: 20170830; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): ES/H/414/01/DC; DATE OF FIRST AUTHORISATION IN EEA: 20170519
2344130 2017/038 Ireland   Start Trial PRODUCT NAME: OZENOXACIN; NAT REGISTRATION NO/DATE: PA1744/003/001 20170616; FIRST REGISTRATION NO/DATE: ES/H/414/01/DC 20170519
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Mallinckrodt
Baxter
Harvard Business School
Dow
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.